ערך בספרים למניה: Passage Bio (PASG)

Passage Bio, Inc. (PASG) expenditures are driven by the development of AAV vectors for the treatment of brain pathologies. The book value per share displayed on the GURU.Markets portal captures asset dynamics, where 1.38 reflects the latest metric value. Passage Bio, Inc. (PASG) aims for the complete cure of rare genetic CNS disorders, although the business is currently in the pre-commercial stage with rising clinical trial costs.

For an investor in Passage Bio, Inc. (PASG), the fundamental valuation of assets is critical when analyzing the cost of gene therapy development. This metric reflects the volume of equity minus liabilities, and the book value per share allows for an assessment of management's financial stability as they push the portfolio through clinical filters, determining the real safety cushion against market optimism.